A Trojan‐Horse‐Like Biomimetic Nano‐NK to Elicit an Immunostimulatory Tumor Microenvironment for Enhanced GBM Chemo‐Immunotherapy

Although the chemo‐ and immuno‐therapies have obtained good responses for several solid tumors, including those with brain metastasis, their clinical efficacy in glioblastoma (GBM) is disappointing. The lack of safe and effective delivery systems across the blood‐brain barrier (BBB) and the immunosuppressive tumor microenvironment (TME) are two main hurdles for GBM therapy. Herein, a Trojan‐horse‐like nanoparticle system is designed, which encapsulates biocompatible PLGA‐coated temozolomide (TMZ) and IL‐15 nanoparticles (NPs) with cRGD‐decorated NK cell membrane (R‐NKm@NP), to elicit the immunostimulatory TME for GBM chemo‐immunotherapy. Taking advantage of the outer NK cell membrane cooperating with cRGD, the R‐NKm@NPs effectively traversed across the BBB and targeted GBM. In addition, the R‐NKm@NPs exhibited good antitumor ability and prolonged the median survival of GBM‐bearing mice. Notably, after R‐NKm@NPs treatment, the locally released TMZ and IL‐15 synergistically stimulated the proliferation and activation of NK cells, leading to the maturation of dendritic cells and infiltration of CD8+ cytotoxic T cells, eliciting an immunostimulatory TME. Lastly, the R‐NKm@NPs not only effectively prolonged the metabolic cycling time of the drugs in vivo, but also has no noticeable side effects. This study may offer valuable insights for developing biomimetic nanoparticles to potentiate GBM chemo‐ and immuno‐therapies in the future. A Trojan‐horse‐like nanoparticle system is designed, which encapsulates biocompatible PLGA‐coated temozolomide (TMZ) and IL‐15 nanoparticles with cRGD peptide‐decorated NK cell membrane (R‐NKm@NPs). Mediated by the NK cell membrane cooperating with cRGD, the R‐NKm@NPs traversed across the blood‐brain barrier (BBB) and targeted glioblastoma (GBM). Notably, the R‐NKm@NPs exhibit good antitumor ability by locally releasing TMZ and IL‐15, eliciting an immunostimulatory tumor microenvironment (TME) and chemo‐immunotherapy response.